Fused heteroaromatic pyrrolidinones

Patent metadata

Field	Value
Publication number	US-9108970-B2
Application number	US-201313886032-A
Country	US
Kind code	B2
Filing date	May 2, 2013
Priority date	Dec 23, 2009
Publication date	Aug 18, 2015
Grant date	Aug 18, 2015

Abstract

Disclosed are compounds of Formula 1,

and pharmaceutically acceptable salts thereof, wherein G, L 1 , L 2 , R 1 , R 2 , R 3 , and R 4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

First claim

What is claimed is:

1. A method of treating a disease or condition by inhibiting SYK in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula 1,

or a pharmaceutically acceptable salt thereof, wherein:
G is C(R 5 );
L 1 and L 2 are each independently selected from —NH— and a bond;…

Assignees

• Takeda Pharmaceutical

Inventors

• Arikawa Yasuyoshi
• Jones Benjamin
• Lam Betty
• Smith Christopher
• Takahashi Masashi
• Dong Qing
• Feher Victoria
• Nie Zhe

Classifications

• A61P7/02

  Human Necessities · mapped topic

• A61P7/00

  Human Necessities · mapped topic

• A61P3/10

  Human Necessities · mapped topic

• A61P37/00

  Human Necessities · mapped topic

• A61P37/08

  Human Necessities · mapped topic